We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TRAK:NYSEReposiTrak, Inc. Analysis

Data as of 2026-09-08 - not real-time

$7.78

Latest Price

8/10Risk

Risk Level: High

Executive Summary

ReposiTrak, Inc. trades at $7.78, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. The last 30 days have lost 9.1%. RSI sits at 38.3, which reads as approaching oversold, and MACD momentum is bearish. Recent trading has carved out support near $7.37 and resistance around $8.75.
Valuation screens as undervalued: a P/E of 21.0 sits below the sector average of 33.3. The average analyst target implies 105.7% above today's level. The 1.01% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 34.6%, a beta of 0.70 and a maximum drawdown of 59.8%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 4/10 long-term conviction.

Top Market Events

Key Insights Using the 2 Stage Free Cash Flow to Equity, ReposiTrak fair value estimate is US$12.Yahoo Finance1monReposiTrak’s Expanding Scan-Based Trading Network Extends into Distribution Centers/WarehousesThe...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 9.73
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • P/E of 21.0 versus sector average of 33.3
  • Trading below the 200-day average of 9.73

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • P/E of 21.0 versus sector average of 33.3
  • Analyst targets imply +105.7% versus the current price
  • Profit margin of 31.0% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth-0.50%
Profit Margin31.05%
P/E Ratio21.0
ROE14.66%
ROA8.41%
Debt/Equity0.69
P/B Ratio2.8
Op. Cash Flow$7.5M
Free Cash Flow$5.3M
Industry P/E33.3

Technical Analysis

TrendBearish
RSI38.3
Support$7.37
Resistance$8.75
MA 20$8.11
MA 50$8.52
MA 200$9.73
MACDBearish
VolumeIncreasing
Fear & Greed Index93.7

Valuation

Fair Value$5.15
Target Price$16.00
Upside/Downside105.66%
GradeUndervalued
TypeBlend
Dividend Yield1.01%

Risk Assessment

Beta0.70
Volatility34.61%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.